您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 抗病毒药物->抗艾滋病药物
处方药:处方药
包装规格: 150毫克/片 60片/盒
计价单位:
   
生产厂家英文名:
VIIV HLTHCARE
该药品相关信息网址1:
http://www.rxlist.com/selzentry-drug.htm
原产地英文商品名:
SELZENTRY 150mg 60tabs
原产地英文药品名:
MARAVIROC
中文参考商品译名:
SELZENTRY 150毫克/片 60片/盒
中文参考药品译名:
马拉维若片
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
HIV
临床试验期:

中文适应病症参考翻译1:
艾滋病
药品信息:
辉瑞公司的马拉维若片(商品名:Selzentry)是l0余年来首个新一类口服HIV治疗药。 剂量规格:马拉维若150mg/片,300mg/片。Selzentry在治疗曾用其它药物治疗过的特异类型HIV感染患者时,遏止病毒进入白细胞,显著减少病毒携带量和增加T细胞计数。 马拉维若是称作CCR5拮抗剂类药的第一个.阻断病毒进入T细胞主要途径的CCR5共同受体。本品在R5病毒进入T细胞前将其阻止在细胞外表面,而不是像所有其它已上市的所有HIV口服药作用于细胞内的病毒。 美国FDA加速批准了马拉维若与其它抗逆转录病毒治疗药合用治疗成人仅可检测出的CCR5一tropicHIV一1病毒(也称为R5病毒)感染,患者体内出现病毒复制和有耐多种抗逆转录病毒治疗药的HIV一1株。可以诊断测试来确定患者是否感染CCR5一tropicHIV一1病毒。CCR5系一某种类型免疫细胞表面的蛋白质。在先前接受HIV药物治疗的患者中,约50%~60%的人血中带有CCR5一tropicHIV一1病毒。此新药对其它药物治疗无效的许多HIV病毒感染者非常重要,为其提供了治疗的新方法。 美国FDA批准马拉维若片上市是基于双盲安慰剂对照临床研究的安全性和有效性结果。选择了1076例患者临床研究,尽管患者先前采用其它HIV药物治疗过,但他们血中仍带有HIV病毒。 加速批准可让优于现有治疗严重或威胁生命疾病药物的新品尽早获准上市。本品批准是基于24周的双盲对照MOTIVATE临床研究数据,美国FDA常规批准马拉维若上市则需要长期的研究报告。在此MOTIVATE临床研究中,接受马拉维若片加优化背景疗法(optimizedbackgroundtherapy,OBT)的患者24周时未检测出携带病毒的例数是单独接受OBT对照组的2倍。在此研究中,接受马拉维若片加OBT治疗的患者较单独接受OBT治疗者显著减少病毒携带量和增加CD4细胞计数。在MOTIVATE临床研究中,接受马拉维若片加OBT治疗的患者疗效为69.7%,单独接受OBT治疗者为66%。 辉瑞公司正向全球各国递交上市申请,新近收到欧盟人用药委员会(CHMP)的可接受函。辉瑞公司准备在美国以外的国家采用Celsentri商品名。在临床研究中.马拉维若片组因不良反应停药率(3.8%)与OBT加安慰剂组停药率(3.8%)相似。本品常见的不良反应是咳嗽、发热、上呼吸道感染、药疹、肌肉骨骼症状、腹痛和眩晕。 Selzentry - Used for: Treating patients with a certain type of HIV infection (CCR5-tropic HIV-1). It is used along with other HIV medicines. Selzentry is a CCR5 coreceptor antagonist. It works by blocking the virus from entering cells. Selzentry is an antiviral medication that prevents certain viral cells from multiplying in your body. Selzentry is used together with other medications. to treat CCR5-tropic human immunodeficiency virus (HIV) type 1. Selzentry is not a cure for HIV or AIDS. Selzentry may also be used for purposes not listed in this medication guide. Selzentry is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. Indication: For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Indications: hiv infection Selzentry, in combination with other antiretroviral agents, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of Selzentry of 48 weeks duration. Both studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI, or enfuvirtide) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with SELZENTRY: Tropism testing is required for the appropriate use of SELZENTRY. Use of Selzentry is not recommended in patients with dual/mixed or CXCR4-tropic HIV-1 as efficacy was not demonstrated in a phase 2 study of this patient group. The safety and efficacy of Selzentry have not been established in treatment-naïve adult patients or pediatric patients.
更新日期: 2014-09-28
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com